Studies on the inhibitory effect of isavuconazole on flumatinib metabolism in vitro and in vivo

As the validated agent for the treatment of chronic myelogenous leukemia (CML), flumatinib is a novel oral tyrosine kinase inhibitor (TKI) with higher potency and selectivity for BCR-ABL1 kinase compared to imatinib. Many patients experience aspergillosis infection and they may start using isavucona...

Full description

Saved in:
Bibliographic Details
Main Authors: Ya-nan Liu (Author), Xinhao Xu (Author), Jingjing Nie (Author), Yingying Hu (Author), Xuegu Xu (Author), Ren-ai Xu (Author), Xiaoxiang Du (Author)
Format: Book
Published: Frontiers Media S.A., 2023-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available